On September 25, 2024 Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, reported it is presenting data about INTASYL, its patented technology platform at the 20th Annual Oligonucleotide Therapeutics Society (OTS) Meeting (Press release, Phio Pharmaceuticals, SEP 25, 2024, View Source [SID1234646864]). The conference will be held from October 6th-9th in Montreal, bringing together leading experts in oligonucleotide research.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Phio’s presentation will focus on how INTASYL can enhance the ex vivo expansion process to improve the functionality and outcomes of adoptive cell therapies such as NK, TIL, or CAR-T. An advantage of the INTASYL technology is its simplified chemical composition, designed to reduce toxicity and improve both tolerability and efficacy, which are concerns in therapeutic development.
Presentation Details are as follows:
Title: INTASYL Self-Delivering RNAi: a Flexible Platform for Cancer Treatment
Poster Number: P180
Poster Session: II
Presenting Author: Melissa Maxwell
Date and Time: October 8 at 3:45-6:45 PM
Location: Centre Mont-Royal, 2000 Mansfield St, Montreal, Quebec